Pacira Biosciences, Inc. (PCRX) - Q2 2024 10-Q Summary
Business Context and Reporting Period
This summary covers the quarterly period ended June 30, 2024. Pacira BioSciences, Inc. is a therapeutic area leader in non-opioid pain management. Its core portfolio includes EXPAREL (long-acting local analgesic), ZILRETTA (extended-release intra-articular injection for osteoarthritis), and iovera (cryoanalgesia device). The company operates as a single reportable segment. Effective January 2, 2024, the company appointed a new Chief Executive Officer.
Key Financial Metrics
| Metric (in thousands) | Q2 2024 | Q2 2023 | YTD 2024 | YTD 2023 |
|---|---|---|---|---|
| Total Revenues | $178,023 | $169,467 | $345,140 | $329,808 |
| Net Product Sales | $176,387 | $169,467 | $342,211 | $328,898 |
| Net Income | $18,886 | $25,763 | $27,865 | $6,227 |
| Diluted EPS | $0.39 | $0.51 | $0.58 | $0.13 |
| Gross Margin | 75% | 72% | 73% | 71% |
| Operating Cash Flow (YTD) | $102,337 (vs. $62,627 YTD 2023) | |||
| Cash & Investments (End of Period) | $404,226 ($247M Cash + $157M Investments) | |||
| Total Debt (Net) | $589,300 |
Material Changes vs. Prior Period
- Revenue Growth: Total revenues increased 5% in Q2 2024 compared to Q2 2023. Net product sales grew 4%, driven by a 29% increase in iovera sales and a 100% increase in veterinary bupivacaine sales. EXPAREL sales grew 1% and ZILRETTA sales grew 5%.
- Profitability: Net income decreased 27% in Q2 2024 ($18.9M) compared to Q2 2023 ($25.8M), primarily due to the absence of a $16.6M gain on contingent consideration recognized in the prior year. However, YTD 2024 net income ($27.9M) significantly exceeded YTD 2023 ($6.2M).
- Debt Restructuring: In May 2024, the company issued $287.5M of 2029 Convertible Senior Notes. Proceeds were used to repurchase $200.0M of 2025 Convertible Senior Notes at a discount, resulting in a $7.5M gain on early extinguishment of debt.
- Share Repurchases: The company initiated a new $150M share repurchase program in May 2024 and immediately repurchased 837,240 shares for $25.1M.
- Restructuring: The company recognized $6.5M in restructuring charges YTD 2024 related to a plan to reallocate resources to commercial portfolios and executive team changes.
Guidance, Outlook, and Risks
- Regulatory Outlook: The Centers for Medicare and Medicaid Services (CMS) proposed a rule for 2025 that would allow separate Medicare reimbursement for EXPAREL at 106% of the Average Sales Price (ASP + 6%) in hospital outpatient and ambulatory surgical center settings, effective January 1, 2025, under the NOPAIN Act.
- Product Pipeline: PCRX-201, a gene therapy for osteoarthritis, received Regenerative Medicine Advanced Therapy (RMAT) designation from the FDA in February 2024. The company is advancing clinical trials for EXPAREL in pediatric and lower extremity nerve block indications.
- Legal Contingencies:
- Generic Competition: In July 2024 (subsequent event), eVenus received FDA approval for a generic version of EXPAREL. Multiple patent infringement litigations are ongoing, with decisions expected shortly.
- Royalty Dispute: A lawsuit regarding royalty obligations to the Research Development Foundation (RDF) is pending trial in September 2024. The company expects to receive $14.5M in royalties paid under protest if the court ruling is upheld.
- MyoScience Litigation: A trial regarding milestone payments from the MyoScience acquisition concluded in September 2023, with a decision expected.
- Liquidity: Management believes existing cash, investments, and operating cash flows are sufficient to fund operations and debt obligations for the next 12 months.
Investor Verification Checklist
- Verify the outcome of the pending patent infringement trials regarding the eVenus generic EXPAREL approval and its potential impact on future revenue.
- Monitor the finalization of the CMS 2025 reimbursement rule for EXPAREL (ASP + 6%) and its impact on pricing and volume.
- Review the status of the RDF royalty litigation trial scheduled for September 2024 and the potential $14.5M recovery.
- Assess the execution of the new $150M share repurchase program and its impact on diluted share count.
- Track the progress of the PCRX-201 clinical trials following its RMAT designation.